Fluproquazone (trade name Tormosyl, RF 46-790 ) was a quinazolinone derivative with potent analgesic, antipyretic, and anti-inflammatory effects discovered by Sandoz.[1][2][3][4] It was withdrawn during development due to liver toxicity.[5]: 370 [6]: 520 

References

  1. ^ Haanaes HR, Benterud UJ, Skoglund LA (November 1986). "RF 46-790 versus paracetamol: effect on post-operative pain". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 24 (11): 598–601. PMID 3491794.
  2. ^ Mohing W, Suckert R, Lataste X (1981). "Comparative study of fluproquazone in the management of post-operative pain". Arzneimittel-Forschung. 31 (5a): 918–20. PMID 6973986.
  3. ^ Wheatley D (May 1982). "Analgesic properties of fluproquazone". Rheumatology and Rehabilitation. 21 (2): 98–100. doi:10.1093/rheumatology/21.2.98. PMID 7043713.
  4. ^ Fankhauser S, Laube W, Marti HR, Schultheiss HR, Vögtlin J, von Graffenried B (1981). "Antipyretic activity of fluproquazone in man". Arzneimittel-Forschung. 31 (5a): 934–5. PMID 6973990.
  5. ^ Lewis JH, Stine JG (2013). "Nonsteroidal Antiinflammatory Drugs and Leukotriene Receptor Antagonists". In Kaplowitz N, DeLeve LD (eds.). Drug-induced Liver Disease (third ed.). Elsevier Inc. ISBN 9780123878175.
  6. ^ Zimmerman HJ (1999). Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Lippincott Williams & Wilkins. ISBN 9780781719520.